The United States needs to curb excessive opioid prescribing and improve access to pain management techniques, suggests a new government study.
It’s no longer a question of if, but when. The life sciences industry has begun its journey to unify applications with the aim of driving greater efficiency across the end-to-end clinical landscape.
Pharmacy benefit manager Express Scripts Holding Co. said it would favor drugmaker Mylan Inc.’s versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies.
Teva Pharmaceutical Industries and South Korea’s Celltrion said the U.S. Food and Drug Administration has accepted for review a biologics application for a biosimilar drug to treat breast cancer.
There were more deaths in patients taking J&J’s experimental rheumatoid arthritis drug sirukumab than among those taking a placebo, FDA staff reviewers said.
Clinical diagnostics company LabCorp announced it is buying private contract research organization Chiltern for $1.2 billion.
FDA Panel Votes to Recommend Dynavax’s Hepatitis B Vaccine; Hepsilav Can Compete With GlaxoSmithKline’s Engerix-B
A U.S. Food and Drug Administration advisory committee gave a thumb’s-up recommendation for Dynavax Technologies Corporation’s Heplisav-B hepatitis B vaccine.
Otsuka Pharmaceutical and H. Lundbeck’s Abilify Maintena (aripiprazole) was approved by the U.S. FDA for the maintenance monotherapy treatment of bipolar I disorder in adults.
U.S. drugmaker AbbVie Inc. reported Q2 2017 earnings that edged past analysts’ expectations, helped by robust demand for the company’s flagship RA drug Humira.